Pemvidutide vs Tirzepatide
A lean-mass-sparing dual vs the approved GIP dual
Pemvidutide (Altimmune) is a GLP-1/glucagon dual agonist notable for preserving lean mass and for liver-disease data; tirzepatide (Mounjaro/Zepbound) is the approved GLP-1/GIP dual with the deeper proven weight loss. Here is how they compare.
Body composition vs total weight loss
Pemvidutide adds glucagon agonism to GLP-1, raising energy expenditure and reducing liver fat. A standout finding in its Phase 2 obesity program was that a high proportion of the weight lost came from fat rather than lean mass — a body-composition advantage that has become a major talking point as the field worries about muscle loss on GLP-1 drugs.
Tirzepatide adds GIP instead, producing the larger headline weight loss (about 22.5% in SURMOUNT-1) with extensive Phase 3 data and approval. Pemvidutide’s reported weight loss is more modest (around 15.6% at 48 weeks in Phase 2) but paired with its lean-mass and MASH story.
The trade-off framing is "deeper proven weight loss" versus "favorable body composition and liver focus." Cross-trial numbers are not directly comparable.
Pemvidutide vs Tirzepatide at a glance
- ⚡Mechanism: GLP-1 + glucagon dual agonist
- ⚡Phase 2: about 15.6% mean weight loss at 48 weeks
- ⚡Notable for a high proportion of fat (vs lean) mass lost
- ⚡Positive Phase 2 MASH / liver-fat data
- ⚡Status: investigational — not FDA approved
- ✓Mechanism: GLP-1 + GIP dual agonist
- ✓SURMOUNT-1: about 22.5% mean weight loss at 72 weeks
- ✓Deeper proven weight loss with large Phase 3 data
- ✓Once-weekly pen; FDA approved and available now
- ✓Has its own positive MASH trial data
Which fits your priorities?
If maximum proven weight loss and availability matter most, tirzepatide is the choice you can act on today. If you are specifically focused on preserving muscle while losing fat, or on liver disease, pemvidutide’s body-composition and MASH profile make it one to watch — but it is investigational and cannot be prescribed yet.
Either way, tracking body measurements and strength alongside scale weight is the only way to see your own fat-vs-lean trajectory, regardless of which drug you use.
Track now, compare later
With no head-to-head trial, your own data is the best input for a future decision. Logging weight, waist and other measurements, side effects, and labs in Shotlee builds an objective baseline so you can compare body composition and outcomes with precision.
Use this comparison as a framework and confirm specifics with your healthcare provider.
Pemvidutide vs Tirzepatide: Frequently Asked Questions
Not in total weight loss — tirzepatide has deeper, approved data (about 22.5%). Pemvidutide’s distinctive strengths are a favorable fat-to-lean body-composition profile and its MASH data, at a more modest ~15.6% in Phase 2. There is no head-to-head trial.
In its Phase 2 program, a high proportion of pemvidutide’s weight loss came from fat rather than lean mass, which is why it is associated with lean-mass preservation. Direct comparisons with tirzepatide do not exist, and both should be paired with resistance training and adequate protein.
Pemvidutide is a GLP-1/glucagon dual agonist (glucagon adds energy expenditure and liver-fat reduction); tirzepatide is a GLP-1/GIP dual agonist. Tirzepatide is FDA approved; pemvidutide is investigational.
No. Pemvidutide (from Altimmune) is investigational and in clinical trials for obesity and MASH. Tirzepatide is approved and available.
Yes. Shotlee logs doses, weight, body measurements, side effects, and labs for your current protocol, free — ideal for tracking body composition over time.
Track Your Body Composition in Shotlee
Free dose logging, weight + measurement trends, and side effect tracking.
